Difference between revisions of "Charles B. Nemeroff"
(New page: {{Template:Pharma_Portal_badge}} '''Charles B. Nemeroff''', M.D., Ph.D., is professor and chairman of the Department of Psychiatry and Behavioral Sciences at the University of Miami Mille...) |
(→Controversies) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 5: | Line 5: | ||
==Controversies== | ==Controversies== | ||
| − | [[GlaxoSmithKline]] Payment Disclosures | + | '''[[GlaxoSmithKline]] Payment Disclosures''' |
In 2008, Nemeroff was accused of failing to disclose $500,000 worth of payments from [[GSK]]. <ref>Goldstein, J.The Wall Street Journal. 3 October 2008. [http://blogs.wsj.com/health/2008/10/03/grassley-says-emory-psychiatrist-didnt-report-500000-in-payments/ Grassley says Emory Psychiatrist Didnt Report 500,000 in Payments] Accessed 3 February 2010.</ref> | In 2008, Nemeroff was accused of failing to disclose $500,000 worth of payments from [[GSK]]. <ref>Goldstein, J.The Wall Street Journal. 3 October 2008. [http://blogs.wsj.com/health/2008/10/03/grassley-says-emory-psychiatrist-didnt-report-500000-in-payments/ Grassley says Emory Psychiatrist Didnt Report 500,000 in Payments] Accessed 3 February 2010.</ref> | ||
At the time, he was the main investigator of a collaborative project between Emory University, [[GSK]] and the US government’s [[National Institute of Mental Health]] investigating ‘five novel GSK antidepressants’. <ref>Grassley, C. 2 October 2008. [http://s.wsj.net/public/resources/documents/SenateLetter081003.pdf Senate Letter] Accessed 2 February 2010.</ref> | At the time, he was the main investigator of a collaborative project between Emory University, [[GSK]] and the US government’s [[National Institute of Mental Health]] investigating ‘five novel GSK antidepressants’. <ref>Grassley, C. 2 October 2008. [http://s.wsj.net/public/resources/documents/SenateLetter081003.pdf Senate Letter] Accessed 2 February 2010.</ref> | ||
| + | |||
| + | '''[[Cyberonics]] Payment Disclosures''' | ||
| + | |||
| + | In 2006, Nemeroff was the primary author of a paper published in [[Neuropsychopharmacology]] and wrote in 'positive terms' about Vagus Nerve Stimulation - a medical device manufactured by [[Cyberonics]] used for refractory eplipsy and treatment-resistant depression. At the time, he was editor-in-chief of the [[ACNP]] journal and head of the Cyberonics advisory board, but failed to disclose financial ties to the company. The [[ACNP]] accused Nemeroff of operating a "slick public relations disinformation campaign, hiring a | ||
| + | ghostwriter, and incestuously placing the article in his own journal". <ref>McHenry L., (2010), Of Sophists and Spin-Doctors: Industry-Sponsored Ghostwriting and the Crisis of Academic Medicine. In: Psychopharmacology Today: Some Issues (A.R. Singh and S.A. Singh eds.), MSM, 8, Jan - Dec 2010, p129-145.</ref> | ||
==Notes== | ==Notes== | ||
Latest revision as of 21:34, 4 February 2010
|
This article is part of the Pharma_Portal project of Spinwatch. |
Charles B. Nemeroff, M.D., Ph.D., is professor and chairman of the Department of Psychiatry and Behavioral Sciences at the University of Miami Miller School of Medicine and UHealth – University of Miami Health System.[1] Previously, he spent 18 years at the Emory University School of Medicine in Atlanta. He is the former Editor-in-Chief of Neuropsychopharmacology, the journal of the American College of Neuropsychopharmacology(ACNP). [2]
Controversies
GlaxoSmithKline Payment Disclosures
In 2008, Nemeroff was accused of failing to disclose $500,000 worth of payments from GSK. [3] At the time, he was the main investigator of a collaborative project between Emory University, GSK and the US government’s National Institute of Mental Health investigating ‘five novel GSK antidepressants’. [4]
Cyberonics Payment Disclosures
In 2006, Nemeroff was the primary author of a paper published in Neuropsychopharmacology and wrote in 'positive terms' about Vagus Nerve Stimulation - a medical device manufactured by Cyberonics used for refractory eplipsy and treatment-resistant depression. At the time, he was editor-in-chief of the ACNP journal and head of the Cyberonics advisory board, but failed to disclose financial ties to the company. The ACNP accused Nemeroff of operating a "slick public relations disinformation campaign, hiring a ghostwriter, and incestuously placing the article in his own journal". [5]
Notes
- ↑ University of MiamiUM Miller School of Medicine Names New Chair of Psychiatry] Accessed 30 January 2010.
- ↑ Emory University.Psychiatry: Emory Accessed 2 February 2010.
- ↑ Goldstein, J.The Wall Street Journal. 3 October 2008. Grassley says Emory Psychiatrist Didnt Report 500,000 in Payments Accessed 3 February 2010.
- ↑ Grassley, C. 2 October 2008. Senate Letter Accessed 2 February 2010.
- ↑ McHenry L., (2010), Of Sophists and Spin-Doctors: Industry-Sponsored Ghostwriting and the Crisis of Academic Medicine. In: Psychopharmacology Today: Some Issues (A.R. Singh and S.A. Singh eds.), MSM, 8, Jan - Dec 2010, p129-145.
